Lipid modification. Cardiovascular risk assessment and the modification of blood lipids for the primary and secondary pr

GUIDELINE TITLE
Lipid modification. Cardiovascular risk assessment and the modification of blood lipids for the primary and secondary prevention of cardiovascular disease.

BIBLIOGRAPHIC SOURCE(S)
National Collaborating Centre for Primary Care. Lipid modification. Cardiovascular risk assessment and the modification of blood lipids for the primary and secondary prevention of cardiovascular disease. London (UK): National Institute for Health and Clinical Excellence (NICE); 2008 May. 37 p. (Clinical guideline; no. 67).

GUIDELINE STATUS
This is the current release of the guideline.

** REGULATORY ALERT **
FDA WARNING/REGULATORY ALERT
Note from the National Guideline Clearinghouse: This guideline references a drug(s) for which important revised regulatory and/or warning information has been released.

July 1, 2009 - Chantix or Champix (Varenicline) and Zyban or Wellbutrin (bupropion or amfebutamone): The U.S. Food and Drug Administration (FDA) notified healthcare professionals and patients that it has required the manufacturers of the smoking cessation aids varenicline (Chantix) and bupropion (Zyban and generics) to add new Boxed Warnings and develop patient Medication Guides highlighting the risk of serious neuropsychiatric symptoms in patients using these products. These symptoms include changes in behavior, hostility, agitation, depressed mood, suicidal thoughts and behavior, and attempted suicide.

abrir aquí para acceder al documento NGC AHRQ completo:
Lipid modification. Cardiovascular risk assessment and the modification of blood lipids for the primary and secondary pr